NEW YORK (GenomeWeb News) – Horizon Discovery said today that Array BioPharma will use its X-MAN human isogenic cell lines to evaluate a target that could be used as a cancer treatment.

Array will evaluate a panel of the X-MAN cell lines carrying specific mutant cancer genes with matched parental genetic backgrounds. Array aims to study the potential utility of its compounds and will share some of the data it generates over the course of the evaluation period, which starts this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.